Provided by Tiger Trade Technology Pte. Ltd.

LEPU BIO

4.235
+0.1152.79%
Volume:11.26M
Turnover:47.89M
Market Cap:7.64B
PE:28.44
High:4.325
Open:4.075
Low:4.055
Close:4.120
52wk High:8.110
52wk Low:3.550
Shares:1.80B
HK Float Shares:1.80B
Volume Ratio:0.97
T/O Rate:0.62%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.149
ROE:24.24%
ROA:-0.09%
PB:4.62
PE(LYR):28.44
PS:6.59

Loading ...

Nomura Assigns HK$138.29 Target Price and "Buy" Rating to Akeso

Stock News
·
Yesterday

LEPU BIO Shares Surge Over 4% as CMG901 Clinical Trial Results Selected for Late-Breaking Abstract and to Be Presented at Presidential Symposium

Stock News
·
Sep 28

Market Insights for Hong Kong Stocks: Fed Rate Hike Odds for October Approach 70%, and China Successfully Launches 26 Low-Orbit Satellite Internet Satellites

Stock News
·
Sep 24

Lepu Biopharma to Present Four Cancer Drug Trial Results at Oncology Conference

MT Newswires Live
·
Sep 23

LEPU BIO's CMG901 and Other Research Results Selected as Late-Breaking Abstracts at 2026 ESMO Congress, With Four Studies Accepted for Presentation

Stock News
·
Sep 23

HK Movers | Innovative Drug Stocks Rally Broadly; LEPU BIO, INNOCARE, AKESO Jump Over 7%

Tiger Newspress
·
Sep 21

Chinese Healthcare Platform 111 Inc Q2 Revenue Falls 28% on Asset-Light Shift

Reuters
·
Sep 17

Lepu Biopharma Interim Results: Product Sales More Than Double, Revenue Up 12%, Profit Slips to RMB24.85 Million

Bulletin Express
·
Sep 16

China's Lepu Biopharma H1 Revenue Rises 12.1% on Higher Drug Sales

Reuters
·
Sep 16

Lepu Biopharma H1 Revenue RMB 371.3 Million

THOMSON REUTERS
·
Sep 16

HK Stock Market Update | Innovative Drug Stocks Face Continued Pullback Amid Shifting Overseas Rate Expectations and Post-2026 Negotiation Uncertainty

Stock News
·
Sep 11

LEPU Bio Shares Jump Over 5% in Afternoon Trading on Strong H1 Revenue Growth and Upcoming Full-Cycle BD Milestone

Stock News
·
Aug 27

Lepu Biopharma (SEHK:2157) Stock Grapples With Profit Quality Concerns

Simply Wall St.
·
Aug 21

Lepu Biopharma FY26 H1 Profit Falls 15.2% to RMB 24.8 Million; Revenue Rises 12.1% to RMB 522.4 Million

Reuters
·
Aug 19

LEPU BIO Sets 19 August 2026 Board Meeting to Approve H1 2026 Results and Assess Interim Dividend

Bulletin Express
·
Aug 07

Lepu Biopharma Sets Board Meeting to Review Interim Results, Consider Dividend

Reuters
·
Aug 07

LEPU BIO Maintains 1.80 Billion Issued Shares and Confirms Public Float Compliance for July 2026

Bulletin Express
·
Aug 03

Hong Kong Stock Movers: LEPU BIO Surges Nearly 4% After Positive Topline Results from Global Phase III CMG901 Trial

Stock News
·
Jul 28

Lepu Biopharma Reports Positive Top-Line Results from Global Phase III Trial of Cmg901 (azd0901)

Reuters
·
Jul 28

Lepu Biopharma Says Phase III CLARITY-Gastric01 Trial Meets Overall Survival Endpoint for Cmg901 in Late-line Gastric Cancer

Reuters
·
Jul 28